Hebei Weimiao Biology Co., LTD 1
Location
  • Home
  • Wholesale Bicalutamide CAS 90357-06-5 for Competitive Pricing and Bulk Orders

nóv . 06, 2024 17:39 Back to list

Wholesale Bicalutamide CAS 90357-06-5 for Competitive Pricing and Bulk Orders



Understanding Wholesale Bicalutamide (CAS 90357-06-5) A Comprehensive Overview


Bicalutamide, designated by the Chemical Abstracts Service (CAS) number 90357-06-5, is an antiandrogen medication widely used in the treatment of prostate cancer. It functions primarily as a non-steroidal antiandrogen, effectively blocking the action of androgens such as testosterone at the androgen receptor level. The synthesis and wholesale distribution of bicalutamide are crucial in ensuring its availability for patients requiring androgen deprivation therapy.


Mechanism of Action


Bicalutamide works by competitively inhibiting the binding of testosterone and dihydrotestosterone (DHT) to androgen receptors in prostate cancer cells. This action results in a decrease in androgenic activities, effectively slowing the progression of hormone-sensitive prostate cancer. It is often used in combination with other treatments, such as luteinizing hormone-releasing hormone (LHRH) agonists or surgical castration, to enhance its therapeutic effectiveness.


Therapeutic Indications


The primary indication for bicalutamide is the treatment of advanced prostate cancer, particularly in cases where the cancer is hormone-sensitive. It is usually prescribed to patients who are undergoing combined androgen blockade or as a monotherapy for those who are intolerant of or resistant to surgical castration. The drug has been shown to improve survival rates and quality of life for patients with this condition.


Dosage and Administration


Bicalutamide is typically administered orally, with a standard dosage of 50 mg once daily. It is essential for patients to follow their healthcare provider's instructions precisely, as improper dosing can lead to decreased effectiveness or increased risk of side effects. It may take several months of treatment for the full benefits of bicalutamide to manifest, and ongoing monitoring by healthcare professionals is crucial to assess treatment efficacy and adjust dosages as necessary.


wholesale bicalutamide cas 90357-06-5

wholesale bicalutamide cas 90357-06-5

Side Effects and Considerations

Like any medication, bicalutamide can cause side effects. Commonly reported side effects include hot flashes, gastrointestinal disturbances, fatigue, and breast tenderness or gynecomastia. More serious risks involve liver function abnormalities and potential cardiovascular effects, necessitating regular liver function tests and close monitoring of cardiovascular health during treatment.


Wholesale Distribution


The wholesale distribution of bicalutamide plays a critical role in ensuring access to this essential medication. Manufacturers and distributors are responsible for adhering to strict regulatory guidelines to maintain product quality and efficacy. The sourcing, storage, and distribution of bicalutamide must comply with Good Distribution Practice (GDP) principles, ensuring that the drug is handled safely and remains effective until it reaches the end user.


The Market Landscape


The demand for bicalutamide remains significant, given the prevalence of prostate cancer globally. The wholesale market for this medication is characterized by a range of suppliers, including large pharmaceutical companies and specialty distributors. Factors influencing the market include patent expiration, competition from generics, and the introduction of novel treatments. With the rise of telemedicine and an increasing patient population, the wholesale distribution channel continually adapts to meet evolving healthcare needs.


Conclusion


Bicalutamide (CAS 90357-06-5) is a vital medication in the fight against prostate cancer. Understanding its mechanisms, uses, and the logistics of its wholesale distribution is essential for healthcare providers, patients, and stakeholders in the pharmaceutical industry. As the healthcare landscape continues to shift, ensuring that effective therapies like bicalutamide remain accessible will be crucial in improving outcomes for patients facing prostate cancer.


Share
Next：

Latest news

If you are interested in our products, you can choose to leave your information here, and we will be in touch with you shortly.


Hit enter to search or ESC to close
is_ISIcelandic
en_USEnglish afAfrikaans sqAlbanian amAmharic arArabic hyArmenian azAzerbaijani euBasque belBelarusian bn_BDBengali bs_BABosnian bg_BGBulgarian caCatalan cebCebuano zh_CNChina zh_TWChina (Taiwan) coCorsican hrCroatian cs_CZCzech da_DKDanish nl_NLDutch eoEsperanto etEstonian fiFinnish fr_FRFrench fyFrisian gl_ESGalician ka_GEGeorgian de_DEGerman elGreek guGujarati htHaitian Creole haHausa hawHawaiian he_ILHebrew hi_INHindi hmnMiao hu_HUHungarian igIgbo id_IDIndonesian gaIrish it_ITItalian jaJapanese jvJavanese knKannada kkKazakh kmKhmer rwRwandese ko_KRKorean ckbKurdish kyKyrgyz loLao laLatin lvLatvian lt_LTLithuanian lbLuxembourgish mk_MKMacedonian mgMalgashi ms_MYMalay ml_INMalayalam mtMaltese miMaori mrMarathi mnMongolian my_MMMyanmar ne_NPNepali nb_NONorwegian nyNorwegian orOccitan psPashto fa_IRPersian pl_PLPolish pt_PTPortuguese pa_INPunjabi ro_RORomanian ru_RURussian smSamoan gdScottish Gaelic sr_RSSerbian stSesotho snShona sdSindhi si_LKSinhala sk_SKSlovak sl_SISlovenian soSomali es_ESSpanish suSundanese swSwahili sv_SESwedish tlTagalog tgTajik ta_INTamil tt_RUTatar teTelugu thThai tr_TRTurkish tkTurkmen ukUkrainian urUrdu ug_CNUighur uz_UZUzbek viVietnamese cyWelsh xhBantu yiYiddish yoYoruba zuZulu is_ISIcelandic